Search

Your search keyword '"Francois, Cedric"' showing total 149 results

Search Constraints

Start Over You searched for: Author "Francois, Cedric" Remove constraint Author: "Francois, Cedric"
149 results on '"Francois, Cedric"'

Search Results

1. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

4. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

5. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial

7. Pegcetacoplan compared with supportive care for 26 weeks for participants with paroxysmal nocturnal hemoglobinuria: a plain language summary

8. Plain language summary of PEGASUS, a study comparing pegcetacoplan with eculizumab for 16 weeks in people with paroxysmal nocturnal hemoglobinuria

10. On the Ethics of Facial Transplantation Research

12. Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood

13. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

14. With complements: C3 inhibition in the clinic.

15. Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

16. MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment

17. Poster: MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment

18. Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

19. Forty-Eight Week Efficacy and Safety of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria and Suboptimal Response to Prior Eculizumab Treatment

20. 3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

21. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

22. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

25. C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials

26. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

27. CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

30. Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

33. US immigration order strikes against biotech

34. APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

35. Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)

36. Genetic Variation in Complement Component 2 of the Classical Complement Pathway is Associated With Increased Mortality and Infection: A Study of 627 Patients With Trauma

37. Investigation of Risk Acceptance in Facial Transplantation

41. Bone Quality in Swine Composite Tissue Allografts: Effects of Combination Immunotherapy

42. Bone Quality and Healing in a Swine Vascularized Bone Allotransplantation Model Using Cyclosporine-Based Immunosuppression Therapy

43. On the Ethics of Facial Transplantation Research

44. Composite tissue allotransplantation in chimeric hosts part II. A clinically relevant protocol to induce tolerance in a rat model

45. Low-dose immunosuppression in a rat hind-limb transplantation model

46. Composite tissue allotransplantation in chimeric hosts: part I. prevention of graft-versus-host disease1

47. New Approaches to Antibody Therapy.

Catalog

Books, media, physical & digital resources